Biological activities of guanidine compounds, 2008 – 2012 update

Bibliography

• Saczewski F, Balewski Ł. Biological activities of guanidine compounds. Expert Opin Ther Patents 2009;19:1417-48
   PubMed Web of Science ®Google Scholar
• Berlinck RGS, Burtoloso ACB, Kossuga MH. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2008;25:919-54
   PubMed Web of Science ®Google Scholar
• Berlinck RGS, Burtoloso ACB, Trindade-Silva AE, et al. The chemistry and biology of organic guanidine derivatives. Nat Prod Rep 2010;27:1871-907
   PubMed Web of Science ®Google Scholar
• Castagnolo D, Schenone S, Botta M. Guanylated diamines, triamines, and polyamines: chemistry and biological properties. Chem Rev 2011;111:5247-300
   PubMed Web of Science ®Google Scholar
• Rauws TRM, Maes BUW. Transition metal-catalyzed N-arylations of amidines and guanidines. Chem Soc Rev 2012;41:2463-97
   PubMed Web of Science ®Google Scholar
• Coles MP. Bicyclic-guanidines, -guanidates and –guanidinium salts: wide ranging applications from a simple family of molecules. Chem Commun 2009;3659-76
   PubMedGoogle Scholar
• Taylor JE, Bull SD, Williams MJ. Amidines, isothioureas, and guanidines as nucleophilic catalysts. Chem Soc Rev 2012;41:2109-21
   PubMed Web of Science ®Google Scholar
• Shao J, Chen W, Giulianotti MA, et al. Palladium-catalyzed C-H functionalization using guanidine as a directing group: ortho arylation and olefination of arylguanidines. Org Lett 2012;14:5452-5
   PubMed Web of Science ®Google Scholar
• Xing H, Zhang Y, Lai Y, et al. Synthesis of symmetrical and unsymmetrical N,N'-diaryl guanidines via copper/N-methylglycine-catalyzed arylation of guanidine nitrate. J Org Chem 2012;77:5449-53
   PubMed Web of Science ®Google Scholar
• Santana AG, Francisco CG, Suarez E, et al. Synthesis of guanidines from azides: a general and straightforward methodology in carbohydrate chemistry. J Org Chem 2010;75:5371-4
   PubMed Web of Science ®Google Scholar
• Sun J, Miller JM, Beig A, et al. Mechanistic enhancement of the intestinal absorption of drugs containing the polar guanidine functionality. Expert Opin Drug Metab Toxicol 2011;7:313-23
   PubMed Web of Science ®Google Scholar
• Cooley CB, Trantow BM, Nederberg F, et al. Oligocarbonate molecular transporters: oligomerization-based syntheses and cell-penetrating studies. J Am Chem Soc 2009;131:16401-3
   PubMed Web of Science ®Google Scholar
• Hamilton SK, Harth E. Molecular dendritic transporter nanoparticle vectors provide efficient intracellular delivery of properties. ACS Nano 2009;3:402-10
   PubMed Web of Science ®Google Scholar
• Bagnacani V, Franceschi V, Fantuzzi L, et al. Lower rim guanidinocalix[4]arenes: macrocyclic nonviral vectors for cell transfection. Bioconjug Chem 2012;23:993-1002
   PubMed Web of Science ®Google Scholar
• Probst G, Xu Y. Small molecule BACE1 inhibitors: a patent literature review (2006-2011). Expert Opinion Ther Patents 2012;22:511-40
   PubMed Web of Science ®Google Scholar
• Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010;9:387-98
   PubMed Web of Science ®Google Scholar
• Astra Zeneca Pharmaceuticals LP. Thiazol-guanidine derivatives useful as a (beta)-related pathologies. US0298340; 2010
   Google Scholar
• Gerritz SW, Zhai W, Shi S, et al. Acyl guanidine inhibitors of beta-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis. J Med Chem 2012;55:9208-23
   PubMed Web of Science ®Google Scholar
• Lopez LC, Dos-Reis S, Espargaro A, et al. Discovery of novel inhibitors of amyloid beta-peptide 1-42 aggregation. J Med Chem 2012;55:9521-30
   PubMedGoogle Scholar
• Schmuck C, Frey P, Heil M. Inhibition of fibril formation of Abeta by guanidiniocarbonyl pyrrole receptors. ChemBioChem 2005;6:628-31
   PubMedGoogle Scholar
• Anzini M, Chelini A, Mancini A, et al. Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino-(6-trifluomethoxy)benzothiazole as neuroprotective agents potentially useful in brain diseases. J Med Chem 2010;53:734-44
   PubMed Web of Science ®Google Scholar
• Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies. US0197670; 2010
   Google Scholar
• Bioalvo – Servicos, Investigcao e Desenvolvimento em Biotechnologia S.A. WO123486; 2009
   Google Scholar
• Ribeiro MMB, Pinto ART, Domingues MM, et al. Chemical conjugation of the neuropeptide kyotorphin and ibuprofen enhances brain targeting and analgesia. Mol Pharm 2011;8:1929-40
   PubMedGoogle Scholar
• University of South Florida. N,N'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints. WO048164; 2010
   Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. NEJM 1995;333:1581-8
   PubMed Web of Science ®Google Scholar
• Katnik C, Guerrero WR, Pennypacker KR, et al. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther 2006;319:1355-65
   PubMed Web of Science ®Google Scholar
• WaPharm AB. Use of hydroxyguanidines. US6599943; 2003
   Google Scholar
• Shire LLC. Prodrugs of guanfacine. US0065796; 2011
   Google Scholar
• Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat 2008;4:499-506
   PubMedGoogle Scholar
• The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin, Universidad del Pais Vasco/Euskal Herriko Unibertsitatea. Guanidine based compounds. WO080818; 2009
   Google Scholar
• The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabe. A2-Adrenoceptor ligands. US0160332; 2010
   Google Scholar
• Universidad del Pais Vasco/Euskal Herriko Unibertsitatea, The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth. Guanidine based compounds. US0331384; 2010
   Google Scholar
• Rodriguez F, Rozas I, Ortega JE, et al. Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 1: toward new antidepressants with heteroatomic linkers. J Med Chem 2007;50:4516-27
   PubMedGoogle Scholar
• Rodriguez F, Rozas I, Ortega JE, et al. Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 2: exploring alkyl linkers for new antidepressants. J Med Chem 2008;51:3304-12
   PubMedGoogle Scholar
• The McLean Hospital Corp., University of Utah Research Foundation. Methods for treatment of psychiatric disorders. WO143534; 2011
   Google Scholar
• Abbot GmbH & Co. KG. Guanidinverbindungen Und Ihre Verwendung als Bindungspartner fuer 5-HT5-Rezeptoren. EP2380885; 2011
   Google Scholar
• Roche Palo Alto LLC. Arylsulfonamidyl tetralin derivatives and uses thereof. US7531577; 2009
   Google Scholar
• Zajdel P, Subra G, Verdie P, et al. Sulfonamides with N-alkyl-N'-dialkylguanidine moiety as 5-HT7 receptor ligands. Bioorg Med Chem Lett 2009;19:4827-31
   PubMedGoogle Scholar
• Neveu C, Lefranc B, Tasseau O, et al. Rational design of low molecular weight, stable, potent, and long-lasting GPR103 Aza-beta3-pseudopeptide agonist. J Med Chem 2012;55:7516-24
   PubMed Web of Science ®Google Scholar
• Ustav Organicke Chemie a Biochemie Akademie ved Ceske Republiky, V.V.I, Fyziologicky Ustav Akademie ved Ceske Republiky, V.V.I. Pregnanolone derivatives substituted in 3alpha-position with the cationic group, method of their production, usage and pharmaceutical preparation involving them. WO110010; 2012
   Google Scholar
• Pryma D, Divgi C. Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors. Nucl Med Biol 2008;35:S1:3-8
   Google Scholar
• Gourand F, Mercey G, Ibazizene M, et al. Chemical delivery system of metaiodobenzylguanidine (MIBG) to the central nervous system. J Med Chem 2010;53:1281-7
   PubMedGoogle Scholar
• Robins EG, Zhao Y, Khan I, et al. Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: novel high-affinity NMDA receptor antagonists for imaging with PET. Bioorg Med Chem Lett 2010;20:1749-51
   PubMedGoogle Scholar
• Santangelo RM, Acker TM, Zimmerman SS, et al. Novel NMDA receptor modulators: an update. Expert Opinion Ther Patents 2012;22:1337-52
   PubMed Web of Science ®Google Scholar
• GE Healthcare Ltd. Method of synthesis. WO141568; 2011
   Google Scholar
• Anderssohn M, Schwedhelm E, Luneburg N, et al. Review article: asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010;7:105-18
   PubMed Web of Science ®Google Scholar
• Marcovecchio ML, Dalton RN, Turner C, et al. Symmetric dimethylarginine, an endogenous marker of glomerular filtration rate, and the risk for microalbuminuria in young people with type 1 diabetes. Arch Dis Child 2010;95:119-24
   PubMed Web of Science ®Google Scholar
• Biocrates Life Sciences AG. Method and use of metabolites for the diagnosis of inflammatory brain injury in preterm born infants. EP2492690; 2011
   Google Scholar
• Busso N, Karababa M, Nobile M, et al. Pharmacological ed to NAD. PLOS 2008;3:e2267; 1-10
   Google Scholar
• Topotarget A/S. Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety. WO121055; 2011
   Google Scholar
• Pishvaian MJ, Marshall JL, Hwang JJ, et al. A phase I trial of GMX1777, an inhibitor of nicotinamide phosphoribosyl transferase (NAMPRT), given as a 24-hour infusion. J Clin Oncol 2009;27:15s
   Google Scholar
• Olesen UH, Christensen MK, Bjorkling F, et al. Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun 2008;367:799-804
   PubMed Web of Science ®Google Scholar
• Kato H, Ito E, Shi W, et al. Efficiency of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res 2010;16:898-911
   PubMedGoogle Scholar
• Takeda Pharmaceutical Co. Ltd. N-substituted oxazinopteridines and oxazinopteridinones. US0220575; 2012
   Google Scholar
• Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharm Ther 2008;118:192-205
   PubMedGoogle Scholar
• Intellikine, Inc. Heterocyclic compounds and uses thereof. WO149937; 2011
   Google Scholar
• Trustees of Dartmouth College. Inhibitors of the trypsin-like site of the proteasome and methods of use thereof. US0214732; 2012
   Google Scholar
• Allergan, Inc. Cyclosporin derivatives for treating inflammatory diseases and conditions. WO138423; 2010
   Google Scholar
• Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites. WO060104; 2011
   Google Scholar
• Cytokine Pharmasciences, Inc. Guanylhydrazones for treatment of postoperative intestinal inflammation. WO039429; 2010
   Google Scholar
• Oke SL, Tracey KJ. From CNI-1493 to the immunological homunculus: physiology of the inflammatory reflex. J Leukoc Biol 2008;83:512-17
   PubMed Web of Science ®Google Scholar
• Kalypsys, Inc. Bicyclic heteroaryl inhibitors of PDE4. WO093924; 2011
   Google Scholar
• Rhode Island Hospital. Stromal derived factor inhibition and CXCR4 blockade. WO112919; 2012
   Google Scholar
• Liang X. CXCR4, inhibitors and mechanisms of action. Chem Biol Drug Des 2008;72:97-110
   PubMedGoogle Scholar
• Zhan W, Liang Z, Zhu A, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem 2007;50:5655-64
   PubMed Web of Science ®Google Scholar
• Lim HD, Adami M, Guaita E, et al. Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430. Br J Pharmacol 2009;157:34-43
   PubMed Web of Science ®Google Scholar
• Anamar AB. Compounds for treatment of inflammation. WO012868; 2011
   Google Scholar
• Lim HD, Smits RA, Bakker RA, et al. Discovery of S-(2-Guanidylethyl)-isothiourea (VUF 8430) as a potent nonimidazole histamine H4 receptor agonist. J Med Chem 2006;49:6650-1
   PubMed Web of Science ®Google Scholar
• Kiss R, Keseru GM. Histamine H4 receptor ligands and their potential therapeutic applications: an update. Expert Opinion Ther Patents 2012;22:205-21
   PubMed Web of Science ®Google Scholar
• Piramal Life Sciences Ltd. Tricyclic guanidine derivatives as sodium-proton exchange inhibitors. US0267690; 2010
   Google Scholar
• Boehringer Ingelheim International GmbH. Pyrrolidinyl and piperidinyl compounds useful as NHE-1 inhibitors. WO005783; 2010
   Google Scholar
• Katholieke Universiteit Leuven. Synucleinopathies. WO094090; 2010
   Google Scholar
• Morshedi D, Aliakbari F. The inhibitory effects of cuminaldehyde on amyloid fibrillation and cytotoxicity of alpha-synuclein. Modares J Med Sci Pathobiol 2012;15:45-60
   Google Scholar
• Mao D, Xu Y, Hu X, et al. Synthesis and Na+/H+ exchanger-1 inhibitory activity of substituted (Quinolinecarbonyl)guanidine derivatives. Chem Biodivers 2009;6:1727-36
   PubMed Web of Science ®Google Scholar
• Lee S, Yi KY, Youn SJ, et al. (2-Aryl-5-methylimidazol-4-ylcarbonyl)guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl)guanidines as NHE-1 inhibitors. Bioorg Med Chem Lett 2009;19:1329-31
   PubMed Web of Science ®Google Scholar
• Schwark JR, Jansen HW, Lang HJ, et al. S3226, a novel inhibitor of Na+/H+ exchanger subtype 3 in various cell types. Pflugers Arch 1998;436:797-800
   PubMedGoogle Scholar
• Miyanga W, Shima Y, Noguchi K, et al. Novel acylguanidine derivatives. US008219; 2011
   Google Scholar
• Rodgers HC, Knox AJ. The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis. Eur Respir J 1999;14:693-6
   PubMed Web of Science ®Google Scholar
• Parion Sciences, Inc. Poly aromatic sodium channel blockers. US0214444; 2009
   Google Scholar
• Kainos Medicine, Inc. Production method of phenyl guanidine salts and their intermediates. WO156355; 2011
   Google Scholar
• Gledhill JR, Montgomery MG, Leslie AGW, Walker JE. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. PNAS 2007;104:13632-7
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Co. (1-Phenyl-2-heteroaryl)ethylguanidine compounds as inhibitors of mitochondrial F1F0 ATP hydrolase. US6916813; 2005
   Google Scholar
• The regents of the University of Michigan. Aryl guanidine F1F0-ATPase inhibitors and related methods. WO030891; 2010
   Google Scholar
• Lycera Corp. Pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof. WO078874; 2012
   Google Scholar
• Lycera Corp. Pyridonyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof. WO078869; 2012
   Google Scholar
• Lycera Corp. Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof. WO078867; 2012
   Google Scholar
• Kotthaus J, Schade D, Muschick N, et al. Structure-activity relationship of novel and known inhibitors of human dimethylarginine dimethylaminohydrolase-1: alkenyl-amidines as new leads. Bioorg Med Chem 2008;16:10205-9
   PubMed Web of Science ®Google Scholar
• Wang Y, Monzingo AF, Hu S, et al. Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide. Biochemistry 2009;48:8624-35
   PubMed Web of Science ®Google Scholar
• UCL Biomedica PLC c/o Finance Division University College of London. Guanidine derivatives as inhibitors of DDAH. US0069331; 2009
   Google Scholar
• Eldrug S.A. Compounds. WO016514; 2009
   Google Scholar
• Tovbin, Dmitry Gennadievich. Urethanes, ureas, amidines and related inhibitors of factor Xa. WO108963; 2011
   Google Scholar
• Nektar Therapeutics Al, Corp. Oligomer-guanidine class conjugates. WO089053; 2009
   Google Scholar
• Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure. WO082328; 2011
   Google Scholar
• Gundewar S, Calvert JW, Iha S, et al. Activation of AMP-activated protein kinase by metformin improves left ventricular function and survival heart failure. Circ Res 2009;104:403-11
   PubMed Web of Science ®Google Scholar
• Inserm, CHU Nantes, Universite de Nantes. 5'-Adenosine monophosphate-activated protein kinase (MAPK) activators for treating pulmonary hypertension. WO103040; 2010
   Google Scholar
• Lantheus Medical Imaging, Inc. Compositions, methods and systems for the synthesis and use of imaging agents. WO143360; 2011
   Google Scholar
• Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetes. WO056726; 2010
   Google Scholar
• Vitae Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use. WO159760; 2011
   Google Scholar
• Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes. US0157399; 2012
   Google Scholar
• Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions. WO150286; 2011
   Google Scholar
• Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and for treatment of obesity and diabetes. US0130472; 2010
   Google Scholar
• Biospherics, Inc. D-Tagatose and biguanide compositions and methods. WO123236; 2011
   Google Scholar
• University of Eastern Finland. Novel prodrugs of metformin. WO100337; 2010
   Google Scholar
• Lynn Megeney, Carol Evans, Abdelmalik Slassi. Treatment of muscle disease characterized by insulin resistance. US0065176; 2012
   Google Scholar
• Tassoni E, Giannessi F, Brunetti T, et al. Novel substituted aminoalkylguanidines as potential antihyperglycemic and food intake-reducing agents. J Med Chem 2008;51:3073-6
   PubMedGoogle Scholar
• Coxon GD, Furman BL, Harvey AL, et al. Benzylguanidines and other galegine analogues inducing weight loss in mice. J Med Chem 2009;52:3457-63
   PubMedGoogle Scholar
• Carafa V, Miceli M, Altucci L, Nebbioso A. Histone deacetylase inhibitors: a patent review (2009 - 2011). Expert Opinion Ther Patents 2013;23:1-17
   PubMed Web of Science ®Google Scholar
• Rotili D, Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Genes Cancer 2011;2:663-79
   PubMedGoogle Scholar
• Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004;119:941-53
   PubMed Web of Science ®Google Scholar
• Lizcano F, Garcia J. Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets. Pharmaceuticals 2012;5:963-90
   Google Scholar
• Zhu Q, Huang Y, Marton LJ, et al. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 2012;42:887-98
   PubMed Web of Science ®Google Scholar
• The Johns Hopkins University, Progen Pharmaceuticals. Compositions and methods for combinations of oligoamines with 2-difluoromethylornithine (DFMO). WO113005; 2011
   Google Scholar
• Deng J, Taheri L, Grande F, et al. Discovery of novel anticancer compounds based on a quinoxalinehydrazine pharmacophore. ChemMedChem 2008;3:1677-86
   PubMed Web of Science ®Google Scholar
• University of Southern California. Discovery of novel anticancer compounds based on conformational sampling of quinoxalinhydrazide pharmacophore. US0160313; 2010
   Google Scholar
• French KJ, Upson JJ, Keller SN, et al. Antitumor activity of sphingosine kinase inhibitors. JPET 2006;318:596-603
   PubMed Web of Science ®Google Scholar
• Nishiuma T, Nishimura Y, Okada T, et al. Inhalation of sphingosine kinase inhibitor attenuates airway inflammation in asthmatic mouse model. Am J Physiol Lung Cell Mol Physiol 2008;294:1085-93
   PubMed Web of Science ®Google Scholar
• French KJ, Schrecengost RS, Lee BD, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9
   PubMed Web of Science ®Google Scholar
• French KJ, Zhuang Y, Maines LW, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. JPET 2010;333:129-39
   PubMed Web of Science ®Google Scholar
• Musc Foundation for Research Development. Sphingo-guanidines and their use as inhibitors of sphingosine kinase. WO078247; 2010
   Google Scholar
• Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007;25:1637-8
   PubMed Web of Science ®Google Scholar
• Universita degli Studi di Firenze. 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors. WO098603; 2011
   Google Scholar
• Zanardi F, Burreddu P, Rassu G, et al. Discovery of subnanomolar arginine-glycine-aspartate-based alphavbeta3/alphavbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem 2008;51:1771-82
   PubMedGoogle Scholar
• Binderup E, Bjorkling F, Hjarnaa PV, et al. EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. Bioorg Med Chem Lett 2005;15:2491-4
   PubMed Web of Science ®Google Scholar
• Gilling A, Majjigapu SR, Sordat B, Vogel P. Synthesis of a C-iminoribofuranoside analog of the nicotinamide phosphoribosyltransferase (NAMPT) inhibitor FK866. Helv Chim Acta 2012;95:34-42
   Google Scholar
• Esposito E, Impellizzeri D, Mazzon E, et al. The NAMPT inhibitor FK866 reverts the damage in spinal cord injury. J Neuroinflammation 2012;9:66-76
   PubMedGoogle Scholar
• Forma Therapeutics, Inc. Guanidine compounds and compositions for the inhibition of NAMPT. WO031199; 2012
   Google Scholar
• Topotarget A/S. Novel cyanoguanidines. WO086835; 2009
   Google Scholar
• Topotarget A/S. Pyridinyl derivatives as inhibitors of enzyme nicotinamide phosphoribosyltransferase. WO142735; 2010
   Google Scholar
• Myrexis, Inc. Compounds and therapeutic uses thereof. WO109441; 2011
   Google Scholar
• Dowling RJO, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33-8
   PubMed Web of Science ®Google Scholar
• Merck Patent GmbH, Inserm (Institut National de la Sante et de la Recherche Medicale). Biguanide compounds and its use for treating cancer. WO147528; 2011
   Google Scholar
• Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 2012;17:1090-9
   PubMed Web of Science ®Google Scholar
• Peukert S, Miller-Moslin K. Small-Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics. ChemMedChem 2010;5:500-12
   PubMed Web of Science ®Google Scholar
• Hadden MK. Hedgehog pathway inhibitors: a patent review (2009 – present). Expert Opinion Ther Patents 2013;23:345-61
   PubMed Web of Science ®Google Scholar
• Universite de Strasbourg, Centre national de la recherche scientifique. Acyl guanidine derivatives modulating the Hedgehog protein signaling pathway. US0196865; 2012
   Google Scholar
• Brozewicz K, Sławinski J. 1-(2-Mercaptobenzenesulfonyl)-3-hydroxyguanidines – Novel potent antiproliferatives, synthesis and in vitro biological activity. Eur J Med Chem 2012;55:384-94
   PubMedGoogle Scholar
• Ueda S, Kato M, Inuki S, et al. Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach. Bioorg Med Chem Lett 2008;18:4124-9
   PubMed Web of Science ®Google Scholar
• Colombo E, Desilets A, Duchene D, et al. Design and Synthesis of Potent, Selective Inhibitors of Matriptase. ACS Med Chem Lett 2012;3:530-4
   PubMed Web of Science ®Google Scholar
• Basu A, Sinha BN, Saiko P, et al. N-Hydroxy-N'-aminoguanidines as anti-cancer lead molecule: QSAR, synthesis and biological evaluation. Bioorg Med Chem Lett 2011;21:3324-8
   PubMedGoogle Scholar
• Qian Y, Zhang H-J, Lv P-C, Zhu H-L. Synthesis, molecular modeling and biological evaluation of guanidine derivatives as novel antitubulin agents. Bioorg Med Chem 2010;18:8218-25
   PubMed Web of Science ®Google Scholar
• Zhang H-Z, Crogan-Grundy C, May C, et al. Discovery and structure-activity relationship of (2-(arylothio)-benzylideneamino)guanidines as a novel series of potent apoptosis inducers. Bioorg Med Chem 2009;17:2852-8
   PubMedGoogle Scholar
• Murtaza G, Rauf MK, Badshah A, et al. Synthesis, structural characterization and in vitro biological screening of some homoleptic copper(II) complexes with substituted guanidines. Eur J Med Chem 2012;48:26-35
   PubMed Web of Science ®Google Scholar
• Zhou H, Liu L, Huang J, et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. J Med Chem 2013;56:1113-23
   PubMed Web of Science ®Google Scholar
• Universitat Zurich. Preparation and uses of guanidinium-modified porphyrins and phthalocyanines. WO028780; 2010
   Google Scholar
• Marina Biotech, Inc. Nucleic acid compounds for inhibiting FGFR3 gene expression and uses thereof. WO139842; 2011
   Google Scholar
• Adami RC, Seth S, Harvie P, et al. An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther 2011;19:1141-51
   PubMedGoogle Scholar
• Biotrom Ltd. Hepatitis C antiviral compositions and methods. WO018609; 2009
   Google Scholar
• Bristol-Myers Squibb Co. Compounds for the treatment of hepatitis C. WO139513; 2011
   Google Scholar
• Lathrop & Gage LLP 4845 Pearl East Circle, Suite 201 Boulder, Co 80301. Small antiviral peptides against hepatitis C virus. US0233868; 2009
   Google Scholar
• Yissum Research Development Co. of The Hebrew University of Jerusalem Ltd. Macrocyclic compounds, compositions comprising them and methods for preventing or treating HIV infection. WO024175; 2011
   Google Scholar
• Trana Discovery, Inc. Antiviral compounds and methods of the use thereof. WO113060; 2011
   Google Scholar
• TSRL, Inc. Neuraminidase inhibitors. WO123856; 2011
   Google Scholar
• Fuzians Biomedicals, Inc., The UAB Research Foundation. Compounds useful as antiviral agents, compositions, and methods of use. WO160024; 2011
   Google Scholar
• TSRL, Inc. Prodrugs of neuraminidase inhibitors. WO129305; 2009
   Google Scholar
• Cadila Healthcare Ltd. Process for the preparation of zanamivir. WO114350; 2012
   Google Scholar
• Cheng T-JR, Weinheimer S, Tarbet EB, et al. Development of oseltamivir phosphonate congeners as anti-influenza agents. J Med Chem 2012;55:8657-70
   PubMedGoogle Scholar
• Liu K-C, Fang J-M, Jan J-T, et al. Enhanced anti-influenza agents conjugated with anti-inflammatory activity. J Med Chem 2012;55:8493-501
   PubMed Web of Science ®Google Scholar
• Manfredi Amedea Giuseppina, CISI S.C.R.L. Consorzio interdisciplinare di studi biomolecolari e applicazioni industriali. Anti-viral agents and compositions thereof. WO145056; 2011
   Google Scholar
• Ferruti Paolo, Cavalli Roberto, Ranucci Elisabetta. Non-viral nucleic acid molecules delivery systems. EP2388016; 2011
   Google Scholar
• Ferruti P, Franchini J, Bencini M, Ranucci E. Prevailingly cationic agmatine-based amphoteric polyamidoamine as a nontoxic, nonhemolytic and “stealthlike” DNA complexing agent and transfection promoter. Biomacromolecules 2007;8:1498-504
   PubMed Web of Science ®Google Scholar
• Achaogen, Inc. Antibacterial derivatives of tobramycin. WO132760; 2010
   Google Scholar
• Achaogen, Inc. Treatment of urinary tract infections with antibacterial aminoglycoside compounds. WO132777; 2010
   Google Scholar
• Achaogen, Inc. Antibacterial derivatives of sisomicin. WO132768; 2010
   Google Scholar
• Achaogen, Inc. Antibacterial aminoglycoside analogs. WO132765; 2010
   Google Scholar
• Achaogen, Inc. Antibacterial aminoglycoside analogs. WO030704; 2010
   Google Scholar
• Deakin University. Dioxolane norbornane/ norbornene compounds suitable as antimicrobial agents to treat bacterial infections. WO099573; 2010
   Google Scholar
• Knobbe Martens Olson & Bear LLP. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof. US0152098; 2010
   Google Scholar
• Polymedix, Inc. Synthetic mimetics of host defense and uses thereof. WO062573; 2010
   Google Scholar
• Instytut Chemii Organicznej, Polska Akademia Nauk. Dendrimeric compounds comprising amino acids, hyperbranched core compound, process for preparation of dendrimeric compounds comprising amino acids and hyperbranched core compound, and use thereof. WO033043; 2010
   Google Scholar
• Allaccem, Inc. Bridged polycyclic compound based compositions for topical and oral applications. WO019611; 2010
   Google Scholar
• Fob Synthesis. Carbapenem antibacterials with Gram-negative activity. WO160020; 2011
   Google Scholar
• Rutgers, The State University of New Jersey, University of Medicine and Dentistry of New Jersey. Antimicrobial agents. WO163610; 2011
   Google Scholar
• Rutgers, The State University of New Jersey, University of Medicine and Dentistry of New Jersey. Antimicrobial agents. WO156626; 2011
   Google Scholar
• Lytix Biopharma AS. Methods of peptide modification. US0143384; 2011
   Google Scholar
• Lytix Biopharma AS. Methods of peptide modification. WO081151; 2009
   Google Scholar
• Lytix Biopharma AS. Therapeutic peptides. WO051692; 2011
   Google Scholar
• Lytix Biopharma AS. Antimicrobial compounds. WO081152; 2009
   Google Scholar
• Allergan, Inc. Combinations of preservatives for ophthalmic compositions. WO127151; 2011
   Google Scholar
• Centre National de la Recherche Scientifique (C.N.R.S.). Novel antimicrobial compositions, use and preparation thereof. EP2386589; 2011
   Google Scholar
• Nosopharm, Institut National de la Recherche Agronomique. Nemaucin, an antibiotic produced by entomopathogenic Xenorhabdus cabanillasii. WO085177; 2012
   Google Scholar
• Lytix Biopharma AS. Bioactive alkaloids. WO035305; 2012
   Google Scholar
• Tadesse M, Strøm MB, Svenson J, et al. Synoxazolidinones A and B: novel bioactive alkaloids from the ascidian Synoicum pulmonaria. Org Lett 2010;12:4752-5
   PubMedGoogle Scholar
• Kline T, Felise HB, Barry KC, et al. Substituted 2-imino-5-arylidenethiazolidin-4-one inhibitors of bacterial type III secretion. J Med Chem 2008;51:7065-74
   PubMed Web of Science ®Google Scholar
• Kline T, Barry KC, Jackson SR, et al. Tethered thiazolidinone dimers as inhibitors of the bacterial type III secretion system. Bioorg Med Chem Lett 2009;19:1340-3
   PubMed Web of Science ®Google Scholar
• Tsou LK, Dossa PD, Hang HC. Small molecules aimed at type III secretion systems to inhibit bacterial virulence. Med Chem Comm 2013;4:68-79
   Google Scholar
• Massachusetts Institute of Technology. US0249051; 2010
   Google Scholar
• Mo S, Krunic A, Pegan SD, et al. An antimicrobial guanidine-bearing sesterterpene from the cultured Cyanobacterium Scytonema sp. J Nat Prod 2009;72:2043-5
   PubMed Web of Science ®Google Scholar
• Rodriguez F, Rozas I, Kaiser M, et al. New bis(2-aminoimidazoline) and bisguanidine DNA minor groove binders with potent in vivo antitrypanosomal and antiplasmodial activity. J Med Chem 2008;51:909-23
   PubMed Web of Science ®Google Scholar
• Arafa RK, Wenzler T, Brun R, et al. Molecular modeling study and synthesis of novel dicationic flexible triaryl guanidines and imidamines as antiprotozoal agents. Eur J Med Chem 2011;46:5852-60
   PubMed Web of Science ®Google Scholar
• McKeever C, Kaiser M, Rozas I. Aminoalkyl derivatives of guanidine diaromatic minor groove binders with antiprotozoal activity. J Med Chem 2013;56:700-11
   PubMed Web of Science ®Google Scholar
• Polymedix, Inc., The Trustees of The University of Pennsylvania. Anti-malarial compounds. WO014573; 2010
   Google Scholar
• The United States of America, as represented by the secretary of the Army, on behalf of U.S. Army Medical Research and Materiel Command. New imidazolidinedione derivatives as antimalarial agents, preparation thereof, and methods of use. WO051129; 2010
   Google Scholar
• Rosenthal PJ. Cysteine proteases of malaria parasites. Int J Parasitol 2004;34:1489-99
   PubMed Web of Science ®Google Scholar
• Julius-Maximilians-Universitat Wurzburg, Technische Universitat Carolowilhelmina za Braunschweig. N-protected guanidine-substituted furans, thiophenes, and pyrrols as cysteine protease inhibitors. WO037536; 2010
   Google Scholar
• University of Georgia Research Foundation, Inc. Anti-trypanosomal peptides and uses thereof. WO129267; 2010
   Google Scholar
• Castagnolo D, Raffi F, Giorgi G, Botta M. Macrocyclization of di-Boc-guanidino-alkylamines related to guazatine components: discovery and synthesis of innovative macrocyclic amidinoureas. Eur J Org Chem 2009;334-7
   Google Scholar
• Manetti F, Castagnolo D, Raffi F, et al. Synthesis of new linear guanidines and macrocyclic amidinourea derivatives endowed with high antifungal activity against Candida spp. and Aspergillus spp. J Med Chem 2009;52:7376-9
   PubMed Web of Science ®Google Scholar
• Universita degli Studi di Siena. Linear and cyclic guanidine derivatives, method of preparation and uses thereof. WO113033; 2009
   Google Scholar
• Straetmans high TAC GmbH. Synergistische Kombination von einem oder mehreren Fungiziden mit Guanidiniumsalzen. EP2196091; 2008
   Google Scholar
• Nosopharm, Institut National de la Recherche Agronomique. Cabanillasin, a new antifungal compound, produced by entomopathogenic xenorhabdus cabanillasii. EP2468718; 2010
   Google Scholar
• Sisay MT, Steinmetzer T, Stirnberg M, et al. Identification of the First Low-Molecular-Weight Inhibitors of Matriptase-2. J Med Chem 2010;53:5523-35
   PubMed Web of Science ®Google Scholar
• Silvestri L, Pagani A, Noi A, et al. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008;8:502-11
   PubMed Web of Science ®Google Scholar
• L'Oreal. Amino acid derivatives; compositions containing them; use as agents for treating human perspiration. WO157612; 2011
   Google Scholar
• L'Oreal. Use of novel amino acid derivatives as agents for treating human perspiration, and compositions containing them. WO157610; 2011
   Google Scholar
• Gencia Corp. Mitochondrial compositions and uses thereof. WO033130; 2009
   Google Scholar
• Massachusetts Institute of Technology. Dendrimer-based excipients for the attenuation of protein aggregation. WO065082; 2012
   Google Scholar
• Trout BL, Wang DIC, Baynes BM. Solution additives for the attenuation of protein aggregation. US0247991; 2008
   Google Scholar
• UCL Business PLC. Process for the preparation of guanidino substituted bi- and polyphenyls that are suitable as small molecule carriers. WO027679; 2009
   Google Scholar
• UCL Business PLC. New compounds. WO097604; 2010
   Google Scholar
• Thermolife International, LLC. Amino acid compositions. US0313042; 2011
   Google Scholar
• Hettiarachchy NS. Bioactive pentapeptides from rice bran and use thereof. US0152180; 2011
   Google Scholar
• Flamel Technologies S.A., Monsanto Technology LLC. N-phosphonomethylglycine guanidine derivative salts. US0172220; 2012
   Google Scholar